Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07676162 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal Cancer

StatusRecruiting
PhasePhase 3
Started2026-08-28
View on ClinicalTrials.gov ↗

Amendment history

2026-09-08
Study Status v2
Re-verified, no change to tracked fields
2026-09-02
Study Identification, Study Status, Contacts/Locations v1
Recruitment opened
Start date2026-07→2026-08-28
Study sitesdetails revised at 1 of 1 site
Study title-58 characters
A Randomized, Open-Label, Controlled, Multicenter Phase III Clinical Study of SHR-A1811 in Combination With Chemotherap [...]
2026-06-23
Original filing
This study adopts a randomized, open-label, positive-controlled, multicenter design, aiming to evaluate the efficacy and safety of SHR-A1811 in combination with chemotherapy and bevacizumab versus standard therapy as first-line treatment for advanced colorectal cancer, and to explore the drug's immunogenicity and pharmacokinetic characteristics.
Trial Details
NCT Number NCT07676162
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions Advanced Colorectal Cancer
Enrollment 300 participants
Start Date 2026-08-28
Primary Completion 2029-09 (estimated)
Study Completion 2029-09 (estimated)
Updated on ClinicalTrials.gov 2026-09-10